The European Commission has published Regulation (EU) 2026/1423, adding chlorpyrifos to Part A of Annex I of the EU POPs Regulation (limit: 0.01 mg/kg), and has adopted a draft amendment listing LC-PFCAs (C9–C21), their salts and related compounds (limits: 0.025 mg/kg and 0.26 mg/kg respectively), which will apply from 16 December 2026. Companies exporting to the EU should monitor these developments and prepare for compliance in advance.
The European Commission’s updated REACH Restrictions Roadmap outlines the EU’s accelerating efforts to phase out high-risk chemicals via grouped control and rolling reviews. Covering 15 adopted measures, 9 pending decisions, and dozens of prospective restrictions—including PFAS, CMRs, and heavy metals—it signals a crucial shift toward substitution-first strategies for industry compliance.
On August 27, 2026, the European Chemicals Agency (ECHA) announced the addition of 10 new substance testing proposals and invited public comments by October 12.
CIRS Testing provides a complete medical device chemical testing service, built around the chemical-substance requirements of the EU MDR, REACH, RoHS, the POPs Regulation, China NMPA/GB, and US FDA / ISO 10993 frameworks.
On June 30, 2026, the European Commission adopted a draft regulation to include Chlorpyrifos in Part A of Annex I to the POPs Regulation. The official regulation will be published in the EU Official Journal in due course, bringing Chlorpyrifos under formal regulatory control.
On June 3, 2026, ECHA released a briefing on the SEAC consultation for the PFAS restriction proposal, receiving 3,511 comments within a 60-day period.
On 30 April 2026, the Official Journal of the European Union published Decision (EU) 2026/878. The decision clearly states that the European Union, on behalf of its Member States, will submit a proposal to the Secretariat of the Stockholm Convention on Persistent Organic Pollutants (hereinafter referred to as "the Convention") to recommend the listing of bis(2-ethylhexyl) tetrabromophthalate (abbreviated as TBPH) in Annex A (Elimination) of the Convention.
Per- and Polyfluoroalkyl Substances (PFAS), commonly known as "forever chemicals", feature extremely stable carbon-fluorine bonds, high bioaccumulation potential and suspected endocrine disrupting properties, leading to stringent regulatory restrictions worldwide. According to OECD statistics, the PFAS family comprises over 10,000 substances. Fluoropolymers including Polytetrafluoroethylene (PTFE), FEP, PFA, PVDF and PCTFE are widely applied in cardiovascular catheters, implant coatings, pacemaker wire insulation, as well as sterile high-barrier packaging for medical devices.
Here are five compelling reasons why PCN notification can become your "compliance accelerator."
Contact Us
